Syntagon Announces New CEO, Changes to Management Team
Leading contract research organisation, Syntagon, has unveiled important changes to its management team. With immediate effect, Dr. Andis Slaitas will replace Dr. Michael Lofthagen as Syntagon CEO.
Andis has been with Syntagon since 2005 and has been instrumental in developing the Syntagon Baltic site, based in Latvia, into a world-class chemistry facility. Prior to his new position, Andis was VP of operations at Syntagon and had responsibility for production, management and operations at our Latvian and Swedish operations.
Before coming to Syntagon, Andis spent more than two years at AstraZeneca where he worked as senior research scientist at the department of preclinical chemistry. During this time Andis was a highly productive medicinal chemist, making more than 100 novel compounds. He was also named as an inventor in several international patents. Andis holds a PhD degree from Karolinska Institute, Sweden.
The ownership of Syntagon will remain with its founders, Michael Lofthagen and Paul Alhadeff, and they will assume positions on the Board of Directors of the company.
“I’m delighted to announce the appointment of Andis as CEO. He has had a huge impact on Syntagon since joining the company in 2005. His competence, experience and energy will serve Syntagon well in the years ahead. Paul and I wish him all the very best,” outgoing CEO Michael Lofthagen says.
In further changes to Syntagon’s management structure, Ulrika Burén has been promoted from QA Associate to QA Officer. Ulrika joined Syntagon in 2002 as Senior Analytical Chemist before moving to the QA Department.
Like Andis, Ulrika worked at AstraZeneca before coming to Syntagon where she worked developing and validating analytical methods for clinical candidates, commercial APIs and final products for some eight years.
For further details on this press release, please contact John Cameron, Syntagon Director of Sales & Marketing Europe at john.cameron@syntagon.se
Syntagon is a leading Scandinavia-based drug development partner. We develop compounds from lead optimisation to Phase III clinical trials using the latest technology and equipment combined with a solid quality system. For more about Syntagon, visit our website at www.syntagon.com, and follow us on Twitter at http://twitter.com/Syntagon.
Tags: